The objective of this contract is to design and synthesis a new plga based nanoparticle with nanoparticle with optimal protein-adjuvant formulation combining both targeting and controlled delivery for…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00013
- Awardee
-
Nanocomposix, Inc. UEI EVQMBF7KC8P3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,040
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Solicitation · SBIRPHS20201 · Posted Jun 21, 2019
- Vaccines Enabling HIV Prevention Targeting Germinal Center Enhancement with Engineered Slow Release Nanoparticles Award Notice · Posted Jun 16, 2020
- Contract value 100% obligated
- $299,040.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92111, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$960 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $300,000 |
About this award
This $299,040 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective is to design and synthesize a new PLGA-based nanoparticle with an optimal protein-adjuvant formulation that combines targeting and controlled delivery for immunization against HIV. This contract was set aside for small businesses and is part of a larger SBIR solicitation from NIAID and the Centers for Disease Control and Prevention (CDC) seeking proposals for innovative R&D to support their mission needs.
Description
The objective of this contract is to design and synthesis a new plga based nanoparticle with nanoparticle with optimal protein-adjuvant formulation combining both targeting and controlled delivery for immunization against HIV.
Quick answers
Who was awarded contract 75N93020C00013?
75N93020C00013 was awarded to Nanocomposix, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2020.
How much is contract 75N93020C00013 worth?
The government has obligated $299,040 on 75N93020C00013.
Was contract 75N93020C00013 competed?
The extent of competition for 75N93020C00013 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award